Camurus AB - ESG Rating & Company Profile powered by AI
Check the end of the webpage for potential risks for Camurus AB based on industry, geography and marketcap. The ESG rating for Camurus AB indicates its reporting of the UN SDGs. This report of Camurus AB uses intelligence from across the internet and also from available documents by Camurus AB.
Camurus AB in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 6.8; made up of an environmental score of 6.0, social score of 8.0 and governance score of 6.4.
6.8
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 294 | SMS Pharmaceuticals Ltd | 6.9 | High |
| 294 | Takeda Pharmaceutical Co Ltd | 6.9 | High |
| 314 | Camurus AB | 6.8 | High |
| 314 | Cassiopea SpA | 6.8 | High |
| 314 | Alpine Immune Sciences Inc | 6.8 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Camurus AB have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Camurus AB disclose current and historical energy intensity?
Sign up for free to unlockDoes Camurus AB report the average age of the workforce?
Sign up for free to unlockDoes Camurus AB reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Camurus AB disclose its ethnicity pay gap?
Sign up for free to unlockDoes Camurus AB disclose cybersecurity risks?
Sign up for free to unlockDoes Camurus AB offer flexible work?
Sign up for free to unlockDoes Camurus AB have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Camurus AB disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Camurus AB conduct supply chain audits?
Sign up for free to unlockDoes Camurus AB disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Camurus AB conduct 360 degree staff reviews?
Sign up for free to unlockDoes Camurus AB disclose the individual responsible for D&I?
Sign up for free to unlockDoes Camurus AB disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Camurus AB disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Camurus AB disclose water use targets?
Sign up for free to unlockDoes Camurus AB have careers partnerships with academic institutions?
Sign up for free to unlockDid Camurus AB have a product recall in the last two years?
Sign up for free to unlockDoes Camurus AB disclose incidents of discrimination?
Sign up for free to unlockDoes Camurus AB allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Camurus AB issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Camurus AB disclose parental leave metrics?
Sign up for free to unlockDoes Camurus AB disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Camurus AB disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Camurus AB disclose the pay ratio of women to men?
Sign up for free to unlockDoes Camurus AB support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Camurus AB disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Camurus AB reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Camurus AB involved in embryonic stem cell research?
Sign up for free to unlockDoes Camurus AB disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Camurus AB disclose its waste policy?
Sign up for free to unlockDoes Camurus AB report according to TCFD requirements?
Sign up for free to unlockDoes Camurus AB disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Camurus AB disclose energy use targets?
Sign up for free to unlockDoes Camurus AB disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Camurus AB have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Camurus AB
These potential risks are based on the size, segment and geographies of the company.
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.